July 5, 2026
UiPath Is Profitable. Stock Still Down Big.
What changes when a software company finally crosses zero.
Hey there, bargain hunter.
There is a specific moment in a software company’s life cycle when the investment thesis shifts completely. Not because revenue accelerated. Not because a new product launched. But because one number crossed zero.
UiPath just crossed zero again. In a more meaningful way.
After going public in April 2021 at a $35 billion valuation, the company spent years burning cash. UiPath achieved its first full-year GAAP profit in fiscal 2026 (ended January 31, 2026), posting $57 million in GAAP operating income for the year. Then in Q1 fiscal 2027, ended April 30, 2026, the company posted $28 million in GAAP operating income for a fiscal first quarter. That matters because Q1 is seasonally the weakest period for enterprise software. Being GAAP profitable in your lightest quarter is a different signal than being profitable only in the big year-end close quarter.
Revenue came in at $418 million, up 17% year over year, ahead of the roughly $397.5 million the Street was expecting. Annual recurring revenue reached $1.901 billion, growing 12%.
The stock is still down nearly 29% year to date.
What’s interesting is why.
No. 1 Stock to Buy for THIS MONDAY
Click here to see how to get positioned ahead of this Monday’s setup!
The transition the market is struggling to price
UiPath made its name in robotic process automation, the software robots that handle repetitive office tasks like data entry, invoice processing, and system integration. Then AI arrived and threatened to make that market look dated. So the company repositioned itself as the orchestration and execution layer for AI agents in the enterprise.
That pivot is showing real traction. Sixteen of UiPath’s top 20 deals in the most recent quarter had AI as part of the deployment. Expansion deals that included AI components were six times larger than those that did not. The Maestro orchestration platform is moving from pilot to production at real enterprise clients. One NZ, for example, reduced mobile provisioning cycles from 10 days to under 10 minutes using the platform, implemented in just five weeks.
The strategic question the market is debating: does an automation vendor still matter once AI agents can write and run software on their own? UiPath’s answer is that enterprises will always need a governed, auditable, controllable layer to orchestrate humans, AI, and automation together in regulated environments. That is not a bad answer. It is also not a settled debate.
What is settled: the balance sheet is clean. The company held $1.42 billion in cash, equivalents, and marketable securities with no debt as of April 30, 2026. The company completed a $1 billion share repurchase program and its board authorized a fresh $500 million program in March 2026. In Q1, the company repurchased 20 million shares at an average price of $11.47 under its 10b5-1 plan. An additional 2 million shares were repurchased at $9.63 after the quarter closed. The buyback activity is systematic rather than discretionary, but the scale of it reflects real confidence in cash flow durability.
Millionaire warns: “Move your money now.”
Larry Benedict generated $274 million in profits for his clients by knowing where money flows when the Federal Reserve shifts.
He’s already identified the one ticker he expects billions to flood into… and he’s giving away the name for free.
Click here to get the full details before the window closes.
The valuation reality
At roughly $11 to $12 per share and a market cap near $6 to $6.5 billion, UiPath trades at approximately 3.2x trailing revenue. That is against a backdrop of 82% GAAP gross margins (83% non-GAAP), a dollar-based net retention rate of 109%, and free cash flow of $130 million in a single quarter.
Compare that to the 50x ARR the market implied at the IPO peak. The valuation compression is essentially complete.
The debate now is not whether UiPath can be profitable. It already is, consistently. The debate is whether it can re-accelerate growth from low-double-digit ARR expansion back toward something more interesting. That requires the agentic AI story to translate into faster net new ARR. At $49 million in Q1, net new ARR is steady but not yet explosive. For context, Q4 fiscal 2026 generated $70 million in net new ARR. Watching that number is more useful than watching the headline revenue beat.
Slight tangent, but it matters: analysts are not uniformly bearish here. Bank of America kept an Underperform but raised its price target to $13. BMO trimmed to $13 from $14 at Market Perform. UBS cut to $12. Morgan Stanley lowered to $15. Street consensus sits around $13.47. The stock is trading near the low end of that range, which is part of what makes it worth watching.
What the Q1 profitability milestone actually changes is structural. When a software company flips from red to black on a consistent basis, funds with profitability mandates can now hold it. It screens into different valuation frameworks. Terminal value assumptions become more defensible. That is not a trading catalyst. It is a slow, grinding shift in who is willing to own the stock.
Don’t dive into options blind – get a “battle-tested” strategy FREE today – ticker included
Ready to dive into options? Don’t go in blind. Dave Aquino’s 11-Hour Options for Beginners guide is so much more than just theory. Inside, he gives you a detailed, plain English walkthrough of his “rinse and repeat” strategy for consistent income in crazy markets, PLUS the exact ticker he’s used nearly 900 times with a 95.3% success rate.
Claim your copy of Dave’s 11-Hour Options for Beginners guide…HERE
The next earnings report lands September 3, 2026. Watch the net new ARR number above all else. Q2 guidance calls for revenue of $395 to $400 million and ARR of $1.929 to $1.934 billion. If net new ARR starts climbing toward $70 to $80 million per quarter again, the story changes faster than the current price suggests. If it stalls in the $40 to $50 million range, the patient-money thesis gets harder to defend.
